India Pharma Q4 Results Preview - U.S. To Drive Performance: Systematix

Systematix Research Report

We expect Q4 earnings performance to be driven by growth in the U.S. India branded formulation growth for most players will remain in the high single digit to low double digit range.

Based on AIOCD AWACS, India pharma market grew by 9% during the quarter. For the acute focussed names, domestic sales will witness QoQ weakness on account of seasonality. In the US, we haven't seen any notable / meaningful new product launches from companies in our coverage, but we might still see a positive trajectory on QoQ basis driven by gRevlimid market share expansion.

Mild cost pressure on account of rising freight cost (Red sea) may be offset by selective softening in active pharma ingredient prices.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.